DXP-006 / Singlomics - LARVOL DELTA

Targeting dermatologic diseases with DXP-006, a half-life extended monoclonal antibody that simultaneously blocks multiple IL1 family pathways (AAD 2026) - "Additionally, DXP-006 effectively reduced IL-1 and IL33 activity in PBMC-based assays and significantly decreased epidermal thickness and PASI scores in a humanized mouse model of imiquimod-induced psoriasis. Taken together, these findings position DXP-006 as a “one-drug, multi-pathway” antagonist capable of simultaneously blocking multiple inflammatory signals. This mechanism offers a promising new strategy for patients with dermatologic or other inflammatory conditions who do not respond adequately to existing single-pathway treatments."

Atopic Dermatitis • Dermatitis • Hidradenitis Suppurativa • Immunology • Psoriasis • IL1A • IL1B • IL1RAP • IL33